Amer Bio Medica
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rap… Read more
Amer Bio Medica (ABMC) - Total Liabilities
Latest total liabilities as of March 2023: $1.12 Million USD
Based on the latest financial reports, Amer Bio Medica (ABMC) has total liabilities worth $1.12 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amer Bio Medica - Total Liabilities Trend (1996–2022)
This chart illustrates how Amer Bio Medica's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Amer Bio Medica Competitors by Total Liabilities
The table below lists competitors of Amer Bio Medica ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CDL INVESTMENT
BE:BXU
|
Germany | €5.50 Million |
|
Medical Intl Tech
OTCGREY:MDLH
|
USA | $885.29K |
|
Toucan Interactive Corp
PINK:TCNT
|
USA | $121.94K |
|
Minehub Technologies Inc
OTCQB:MHUBF
|
USA | $1.67 Million |
Liability Composition Analysis (1996–2022)
This chart breaks down Amer Bio Medica's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amer Bio Medica's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amer Bio Medica (1996–2022)
The table below shows the annual total liabilities of Amer Bio Medica from 1996 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $3.61 Million | +27.63% |
| 2021-12-31 | $2.83 Million | -11.16% |
| 2020-12-31 | $3.18 Million | +10.95% |
| 2019-12-31 | $2.87 Million | +9.42% |
| 2018-12-31 | $2.62 Million | +15.56% |
| 2017-12-31 | $2.27 Million | -3.32% |
| 2016-12-31 | $2.35 Million | -17.28% |
| 2015-12-31 | $2.84 Million | -8.75% |
| 2014-12-31 | $3.11 Million | -14.33% |
| 2013-12-31 | $3.63 Million | +6.24% |
| 2012-12-31 | $3.42 Million | +4.56% |
| 2011-12-31 | $3.27 Million | -2.74% |
| 2010-12-31 | $3.36 Million | -8.30% |
| 2009-12-31 | $3.66 Million | -24.93% |
| 2008-12-31 | $4.88 Million | +20.33% |
| 2007-12-31 | $4.05 Million | +36.04% |
| 2006-12-31 | $2.98 Million | +24.95% |
| 2005-12-31 | $2.38 Million | -5.99% |
| 2004-12-31 | $2.54 Million | +25.84% |
| 2003-12-31 | $2.02 Million | -13.40% |
| 2002-12-31 | $2.33 Million | -14.82% |
| 2001-12-31 | $2.73 Million | +49.59% |
| 2000-12-31 | $1.83 Million | +24.97% |
| 1999-12-31 | $1.46 Million | +192.40% |
| 1998-12-31 | $500.00K | +31.53% |
| 1997-12-31 | $380.15K | 0.00% |
| 1996-12-31 | $380.15K | -- |